Work

Abstract 2419: A phase Ib-IIa study evaluating the nanopharmaceutical CRLX101 in combination with bevacizumab in the treatment of patients (pts.) with advanced renal cell carcinoma.

Year: 2013

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2013-2419

Authors: Stephen M. Keefe, Roger B. Cohen, Scott Eliasof, Edward G. Garmey, Meliessa Hennessy, Kristine M. Mykulowicz, Daniel A. Pryma, Naomi Haas

Institutions: Abramson Cancer Center, Cerulean Pharma (United States)

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1971927952

Cites:

Cited by: 1

Related to: 10